• Dr. Leavenworth joined UAB Neurosurgery as an Assistant Professor on Oct. 1, 2016. Previously, Dr. Leavenworth was at the Dana-Farber Cancer Institute at Harvard University. Dr. Leavenworth completed medical school at Nantong University (NTU) School of Medicine, Nantong, Jiangsu, China. She then finished her PhD training in molecular biology, microbiology and biochemistry with a focus on immunology at Southern Illinois University School of Medicine. She was at Harvard Medical School since 2009 serving as a research fellow (Postdoc) and then as an instructor.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Editorial: Macrophage immunity and metabolism in cancer: Novel diagnostic and therapeutic strategiesFrontiers in Immunology.  13. 2022
    2022 Structure-Activity Relationship Study of Momordica Saponin II Derivatives as Vaccine AdjuvantsJournal of Medicinal Chemistry.  65:14589-14598. 2022
    2022 Editorial: Dendritic cell-primed T cells in anti-tumor immune responses and relevant vaccine strategiesFrontiers in Immunology.  13. 2022
    2022 Contribution of Dysregulated B-Cells and IgE Antibody Responses to Multiple SclerosisFrontiers in Immunology.  13. 2022
    2022 AIMing 2 promote lupus by targeting helpers.Clinical and Translational Medicine.  12:e844. 2022
    2022 Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB StudyClinical Cancer Research.  28:498-506. 2022
    2022 Editorial: Immune Cell Lineage Reprogramming in CancerFrontiers in Immunology.  12. 2022
    2022 Targeting the TREM1-positive myeloid microenvironment in glioblastomaNOA.  4. 2022
    2021 Author Correction: Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma murine model (Scientific Reports, (2021), 11, 1, (15384), 10.1038/s41598-021-94887-x)Scientific Reports.  11. 2021
    2021 Dysregulated follicular regulatory T cells and antibody responses exacerbate experimental autoimmune encephalomyelitisJournal of Neuroinflammation.  18. 2021
    2021 Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma murine modelScientific Reports.  11. 2021
    2021 Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockadeMolecular Cancer.  20. 2021
    2021 RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity 2021
    2021 Lineage Reprogramming of Effector Regulatory T Cells in CancerFrontiers in Immunology.  12. 2021
    2020 Group II muscarinic acetylcholine receptors attenuate hepatic injury via Nrf2/ARE pathwayToxicology and Applied Pharmacology.  395. 2020
    2020 Erratum: Control of Germinal Center Localization and Lineage Stability of Follicular Regulatory T Cells by the Blimp1 Transcription Factor (Cell Reports (2019) 29(7) (1848–1861.e6), (S2211124719313129), (10.1016/j.celrep.2019.10.012))Cell Reports.  31. 2020
    2020 Angiostrongylus cantonensis Galectin-1 interacts with Annexin A2 to impair the viability of macrophages via activating JNK pathwayParasites and Vectors.  13. 2020
    2019 Deletion of the RNA regulator HuR in tumor-associated microglia and macrophages stimulates anti-tumor immunity and attenuates glioma growthGlia.  67:2424-2439. 2019
    2019 Control of Germinal Center Localization and Lineage Stability of Follicular Regulatory T Cells by the Blimp1 Transcription FactorCell Reports.  29:1848-1861.e6. 2019
    2019 Towards clinical translation of CD8+ regulatory T cells restricted by non-classical major histocompatibility complex Ib moleculesInternational Journal of Molecular Sciences.  20. 2019
    2019 Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastomaCell Stress.  3:47-65. 2019
    2018 Chromatin remodeling by the NuRD complex regulates development of follicular helper and regulatory T cells 2018
    2018 CD8+ T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patientsClinical Immunology.  190:64-73. 2018
    2018 Lymphocytes contribute to the pathophysiology of neonatal brain injuryFrontiers in Neurology.  9. 2018
    2018 γδ T Cells Contribute to Injury in the Developing BrainAmerican Journal of Pathology.  188:757-767. 2018
    2018 Alphavirus Replicon DNA vectors expressing Ebola GP and VP40 antigens induce humoral and cellular immune responses in miceFrontiers in Microbiology.  8. 2018
    2017 γδT cells but not αβT cells contribute to sepsis-induced white matter injury and motor abnormalities in miceJournal of Neuroinflammation.  14. 2017
    2017 Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002 2017
    2017 Modulation of the intratumoral immune landscape by oncolytic herpes simplex virus virotherapyFrontiers in Oncology.  7. 2017
    2017 The Role of Microglia and Macrophages in CNS Homeostasis, Autoimmunity, and CancerJournal of Immunology Research.  2017. 2017
    2015 Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity 2015
    2015 A p85α-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cellsNature Immunology.  16:96-106. 2015
    2015 NK cell-based cancer immunotherapy: from basic biology to clinical application 2015
    2015 Intracellular osteopontin regulates homeostasis and function of natural killer cells 2015
    2014 The effect of osteopontin and osteopontin-derived peptides on preterm brain injuryJournal of Neuroinflammation.  11. 2014
    2014 The immune response after hypoxia-ischemia in a mouse model of preterm brain injuryJournal of Neuroinflammation.  11. 2014
    2013 Amelioration of arthritis through mobilization of peptide-specific CD8 + regulatory T cellsJournal of Clinical Investigation.  123:1382-1389. 2013
    2011 Mobilization of natural killer cells inhibits development of collagen-induced arthritis 2011
    2010 Analysis of the cellular mechanism underlying inhibition of EAE after treatment with anti-NKG2A F(ab′)2 2010
    2009 SUMO conjugation contributes to immune deviation in nonobese diabetic mice by suppressing c-Maf transactivation of IL-4Journal of Immunology.  183:1110-1119. 2009
    2009 Engagement of transgenic Ly49A inhibits mouse CD4 cell activation by disrupting T cell receptor, but not CD28, signalingCellular Immunology.  257:88-96. 2009
    2007 c-Maf interacts with c-Myb to down-regulate Bcl-2 expression and increase apoptosis in peripheral CD4 cellsEuropean Journal of Immunology.  37:2868-2880. 2007


    Year Title Altmetric
    2023 Analysis of the In Vivo Function of Follicular Regulatory T (TFR) Cells in the Regulation of Antibody Response.  3-13. 2023

    Research Overview

  • Dr. Leavenworth's main research interest is to understand the mechanisms of self-tolerance underlying the innate and adaptive immune responses, with the long-term goal of translating these findings into new therapeutic approaches for the treatment of immune disorders. Her current research is focused on the definition and manipulation of effector and regulatory subsets within the inflamed (central nervous system) or tumor microenvironment, seeking effective immunotherapeutic approaches to these disorders. Dr. Leavenworth's lab has also been evaluating immune responses to oncolytic HSV-based therapies of patients with recurrent gliomas, which are currently in Phase I trials. Combined with murine glioma models, her lab is dissecting mechanisms underpinning the intersection of brain tumor, immunity and oncolytic virotherapy with the goal of stratifying patients for this therapy and developing new or combined immunotherapies. The research projects at Dr. Leavenworth's lab are supported by the internal and extramural funding from the National Institutes of Health (NIH) and the US. Department of Defense (DoD).
  • Education And Training

  • Doctor of Philosophy in Biomedical Sciences, Southern Illinois University/Carbondale 2009
  • Doctor of Medicine, Nantong University 2001
  • Full Name

  • Jianmei Leavenworth